Bozonnat, Alizée; Beylot-Barry, Marie; Dereure, Olivier; D'Incan, Michel; Quereux, Gaëlle; Guenova, Emmanuella; Perier-Muzet, Marie; Dalle, Stephane; Grange, Florent; Viguier, Manuelle-Anne; Ram-Wolff, Caroline; Feldmeyer, Laurence; Beltraminelli, Helmut; Bonnet, Nathalie; Amatore, Florent; Maubec, Eve; Franck, Nathalie; Machet, Laurent; Chasset, François; Brunet-Possenti, Florence; ... (2024). Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort study. EClinicalMedicine, 73(102679) Elsevier 10.1016/j.eclinm.2024.102679
|
Text
1-s2.0-S258953702400258X-main.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial (CC-BY-NC). Download (507kB) | Preview |
BACKGROUND
Sézary syndrome is an extremely rare and fatal cutaneous T-cell lymphoma (CTCL). Mogamulizumab, an anti-CCR4 monoclonal antibody, has recently been associated with increased progression-free survival in a randomized clinical trial in CTCL. We aimed to evaluate OS and prognostic factors in Sézary syndrome, including treatment with mogamulizumab, in a real-life setting.
METHODS
Data from patients with Sézary (ISCL/EORTC stage IV) and pre-Sézary (stage IIIB) syndrome diagnosed from 2000 to 2020 were obtained from 24 centers in Europe. Age, disease stage, plasma lactate dehydrogenases levels, blood eosinophilia at diagnosis, large-cell transformation and treatment received were analyzed in a multivariable Cox proportional hazard ratio model. This study has been registered in ClinicalTrials (SURPASSe01 study: NCT05206045).
FINDINGS
Three hundred and thirty-nine patients were included (58% men, median age at diagnosis of 70 years, Q1-Q3, 61-79): 33 pre-Sézary (9.7% of 339), 296 Sézary syndrome (87.3%), of whom 10 (2.9%) had large-cell transformation. One hundred and ten patients received mogamulizumab. Median follow-up was 58 months (95% confidence interval [CI], 53-68). OS was 46.5% (95% CI, 40.6%-53.3%) at 5 years. Multivariable analysis showed that age ≥ 80 versus <50 (HR: 4.9, 95% CI, 2.1-11.2, p = 0.001), and large-cell transformation (HR: 2.8, 95% CI, 1.6-5.1, p = 0.001) were independent and significant factors associated with reduced OS. Mogamulizumab treatment was significantly associated with decreased mortality (HR: 0.34, 95% CI, 0.15-0.80, p = 0.013).
INTERPRETATION
Treatment with mogamulizumab was significantly and independently associated with decreased mortality in Sézary syndrome.
FUNDING
French Society of Dermatology, Swiss National Science Foundation (IZLIZ3_200253/1) and SKINTEGRITY.CH collaborative research program.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology |
UniBE Contributor: |
Feldmeyer, Laurence, Beltraminelli, Helmut |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
2589-5370 |
Publisher: |
Elsevier |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
16 Jul 2024 15:00 |
Last Modified: |
16 Jul 2024 15:30 |
Publisher DOI: |
10.1016/j.eclinm.2024.102679 |
PubMed ID: |
39007062 |
Uncontrolled Keywords: |
Cutaneous T-cell lymphoma Immunotherapy Mogamulizumab Monoclonal antibody Sézary syndrome |
BORIS DOI: |
10.48350/199015 |
URI: |
https://boris.unibe.ch/id/eprint/199015 |
Actions (login required)
 |
Edit item |